Disease states on treatment
| Non-switchers (n=437) | Switchers (n=77) | |||||
|---|---|---|---|---|---|---|
| 1st TNFi | 1st TNFi | 2nd TNFi | ||||
| 3 Months (n=362) | 3 Months (n=63) | Last observation* (n=68) | 3 Months (n=62) | p Value† | p Value‡ | |
| BASFI (0–10)§ | 2.3 (0.7–4.0) | 4.7 (1.5–6.0) | 5.3 (2.4–7.1) | 3.3 (1.6–5.7) | 0.009 | 0.38 |
| BASDAI (0–10)§ | 2.6 (1.3–4.4) | 4.8 (3.3–7.0) | 6.1 (3.1–7.5) | 4.1 (1.9–6.1) | 0.007 | 0.69 |
| ASDAS§ | 1.76 (1.20–2.47) | 2.82 (1.32–3.75) | 3.47 (1.70–4.21) | 2.33 (1.55–3.28) | 0.007 | 0.70 |
| ESR (mm/h) | 6 (3–12) | 7 (4–14) | 8 (4–32) | 9 (4–17) | 0.006 | 0.32 |
| CRP (mg/l) | 5 (2–6) | 5 (3–8) | 5 (3–14) | 5 (3–7) | 0.01 | 0.57 |
| Patient global VAS (mm) | 21 (9–43) | 31 (12–53) | 59 (26–75) | 34 (18–55) | 0.001 | 0.45 |
| Pain VAS (mm) | 19 (6–36) | 28 (12–52) | 53 (22–66) | 33 (12–53) | 0.001 | 0.27 |
| Fatigue VAS (mm) | 31 (12–63) | 49 (22–76) | 55 (26–76) | 34 (18–55) | 0.02 | 0.10 |
| Physician global VAS (mm) | 10 (5–19) | 17 (7–28) | 21 (11–42) | 20 (10–32) | <0.001 | 0.22 |
| SF-36 PCS | 41 (33–49) | 37 (29–45) | 30 (25–41) | 35 (27–42) | 0.001 | 0.04 |
| SF-36 MCS | 53 (44–57) | 52 (38–57) | 45 (36–53) | 49 (34–57) | 0.09 | 0.63 |
| SF-6D | 0.70 (0.60–0.83) | 0.64 (0.57–0.75) | 0.60 (0.51–0.70) | 0.62 (0.53–0.75) | <0.001 | 0.33 |
Values are median (IQR).
↵* 3 months, n=14; 6 months, n=28; 1 year, n=10; 2 years, n=8; 3 years, n=6; 4 years, n=2.
↵† Non-switchers first TNFi vs switchers second TNFi (ranked analysis of covariance adjusted for baseline).
↵‡ Switchers first TNFi (3 months) vs switchers second TNFi (mixed modelling adjusted for baseline).
↵§ BASDAI, BASFI and ASDAS data were not available for all patients (see details in text).
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; MCS, mental components summary; PCS, physical components summary; SF-36, 36-item Short-Form Health Survey; TNFi, tumour necrosis factor inhibitor; VAS, Visual Analogue Scale.